During the past decade, Kumamoto University conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kumamoto University" #1 sponsor was "Kumamoto University" with 3 trials, followed by "Wakayama Medical University" with 2 trials sponsored, "Boston University" with 1 trials sponsored, "Mie University" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kumamoto University" #1 collaborator was "Food and Drug Administration (FDA)" with 1 trials as a collaborator and "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Kumamoto University" are "Coronary Artery Disease" (3 trials), "Cardiac CT" (1 trials), "Colorectal Cancer" (1 trials), "Familial Amyloid Polyneuropathy" (1 trials) and "Familial Amyloidosis" (1 trials). Many other conditions were trialed in "Kumamoto University" in a lesser frequency.

Most popular intervention types in "Kumamoto University" are "Drug" (3 trials), "Other" (2 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]" (1 trials), "Conventional procedure" (1 trials), "Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials), "Isolation procedure (RAMPS procedure)" (1 trials) and "Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kumamoto University" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Kumamoto University". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Kumamoto University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kumamoto University, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".